Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Statin Treatment on Arterial Wall Inflammation as Assessed With 68Ga-DOTATATE PET-CT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 50 years and older~2. Diagnosed with diabetes mellitus type 2 and using oral glucose lowering therapy, insulin or combined glucose lowering therapy.~3. Not on statin therapy or willing to stop with current statin therapy for 6 weeks prior to visit 2.~4. HbA1c values below 65 mmol/L.~5. Patients with stable diabetes mellitus, i.e. no changes in type of glucose lowering therapy and / or dosage of oral glucose lowering therapy in the past three months. No more than 20% change in dosage of insulin therapy (short and long acting) in the last three months.~Exclusion Criteria:~1. History of cardiovascular disease (previous CV-event (MI / stroke) or known coronary artery disease (including acute coronary syndrome).~2. History of chronic kidney disease stage 3b - 5, defined as a CKD-EPI value of \< 45 ml/min/1,73m2~3. Malignant diseases or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator.~4. Chronic or recent (\< 1 month) infections and/or clinical signs of acute infection.~5. History of auto-immune diseases.~6. Standard contra-indications to 68Ga-Dotatate PET, and CT based on physicians experience and current practices.~7. Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.~8. Planned radiation exposure in the next year due to participation in a research project with radiation exposure or for clinical reasons.~9. Elevated liver enzymes (\> 2 ULN of liver transaminases), acute liver failure or known liver disease.~10. Prior medium to severe statin-related side effects or statin related hypersensitivity, i.e.~    (severe) muscle pains with and/or without myopathy .~11. The concomitant use of statin contra-indicated drugs, including the use of CYP3A4 inhibitors (i.e. erytromycin, dilthiazem, amiodaron, verapamil, fluconazole, ciclosporin, stiripentol, itraconazol, ketoconazol, voriconazol, posaconazol, clarithromycin, ..), systemic use of fusidic acid and ciclosporin.~12. Any contra-indications to the use of statins.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention arm (Type: EXPERIMENTAL): Atorvastatin 40mg once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).